NL300808I1 - - Google Patents

Info

Publication number
NL300808I1
NL300808I1 NL300808C NL300808C NL300808I1 NL 300808 I1 NL300808 I1 NL 300808I1 NL 300808 C NL300808 C NL 300808C NL 300808 C NL300808 C NL 300808C NL 300808 I1 NL300808 I1 NL 300808I1
Authority
NL
Netherlands
Prior art keywords
factor viii
inhibitory antibodies
amino acid
modified factor
loci
Prior art date
Application number
NL300808C
Other languages
English (en)
Dutch (nl)
Other versions
NL300808I2 (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL300808I1 publication Critical patent/NL300808I1/nl
Publication of NL300808I2 publication Critical patent/NL300808I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Steroid Compounds (AREA)
NL300808C 2000-03-10 2016-05-09 susoctocog alfa NL300808I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (2)

Publication Number Publication Date
NL300808I1 true NL300808I1 (enExample) 2016-05-18
NL300808I2 NL300808I2 (nl) 2020-12-21

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300808C NL300808I2 (nl) 2000-03-10 2016-05-09 susoctocog alfa

Country Status (35)

Country Link
US (3) US6458563B1 (enExample)
EP (1) EP1280540B1 (enExample)
JP (1) JP4044337B2 (enExample)
KR (1) KR100485525B1 (enExample)
CN (1) CN1191360C (enExample)
AT (1) ATE391512T1 (enExample)
AU (2) AU2001238416B2 (enExample)
BE (1) BE2016C024I2 (enExample)
BR (2) BR122013026957A8 (enExample)
CA (1) CA2400295C (enExample)
CY (2) CY1108179T1 (enExample)
CZ (1) CZ298250B6 (enExample)
DE (1) DE60133541T2 (enExample)
DK (1) DK1280540T3 (enExample)
EE (1) EE05075B1 (enExample)
ES (1) ES2304379T3 (enExample)
FR (1) FR16C0016I2 (enExample)
HU (2) HU227804B1 (enExample)
IL (2) IL151371A0 (enExample)
LT (1) LTC1280540I2 (enExample)
LU (1) LU93049I2 (enExample)
ME (1) MEP8209A (enExample)
MX (1) MXPA02008798A (enExample)
NL (1) NL300808I2 (enExample)
NO (2) NO331935B1 (enExample)
NZ (1) NZ520799A (enExample)
PL (1) PL202936B1 (enExample)
PT (1) PT1280540E (enExample)
RS (1) RS50364B (enExample)
RU (1) RU2285724C2 (enExample)
SI (1) SI1280540T1 (enExample)
SK (1) SK286205B6 (enExample)
UA (1) UA75064C2 (enExample)
WO (1) WO2001068109A1 (enExample)
ZA (1) ZA200206810B (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
EP1351986A2 (en) * 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
CA2461443C (en) * 2001-10-05 2011-07-12 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
MXPA04005079A (es) * 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP4644663B2 (ja) * 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
PT1636261E (pt) * 2003-06-26 2007-11-08 Merck Patent Gmbh Proteínas trombopoietina com propriedades melhoradas
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US7855274B2 (en) * 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
JP2007536230A (ja) * 2004-05-03 2007-12-13 エモリー ユニバーシティ ブタＢドメイン欠損ｆＶＩＩＩの投与方法
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
US7632921B2 (en) * 2004-11-12 2009-12-15 Bayer Healthcare Llc Site-directed modification of FVIII
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN101379077A (zh) 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
DK2007885T3 (da) * 2006-04-11 2010-11-08 Csl Behring Gmbh Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
EP2209908B1 (en) 2007-11-01 2014-09-03 University Of Rochester Recombinant factor viii having increased stability
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
ES2966234T3 (es) 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
CA2780763A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
CA2816575C (en) * 2010-11-05 2019-06-11 Baxter Healthcare S.A. A new variant of antihemophilic factor viii having increased specific activity
EA201370151A1 (ru) * 2011-01-05 2013-11-29 Экспрешен Терапетикс, Ллс Высокопродуктивная суспензионная клеточная линия, система и способ ее получения
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
DK2729161T3 (en) 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
CN111499761A (zh) 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
BR112014017111A8 (pt) 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
AU2013290173B2 (en) 2012-07-11 2018-02-15 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
WO2014089541A2 (en) 2012-12-07 2014-06-12 Haplomics, Inc. Factor viii mutation repair and tolerance induction
DK2956477T4 (da) 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
EP3666283B1 (en) 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
HK1223302A1 (zh) 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 具有xten的凝血酶可裂解连接子和其用途
EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015059121A1 (en) 2013-10-22 2015-04-30 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
PH12016501323B1 (en) 2014-01-10 2022-04-29 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
EP3107561A4 (en) * 2014-02-19 2017-12-20 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
SG11201804070XA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EP3374388A1 (en) 2015-11-13 2018-09-19 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
EP3476937A4 (en) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US11633504B2 (en) 2017-05-09 2023-04-25 Emory University Nucleic acids encoding clotting factor variants and their use
TWI904068B (zh) 2017-08-09 2025-11-11 美商生物化學醫療公司 核酸分子及其用途
SG11202007114VA (en) 2018-02-01 2020-08-28 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor viii
MX2020010369A (es) 2018-04-04 2020-10-22 Sigilon Therapeutics Inc Particulas implantables y metodos relacionados.
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
AU2019306194A1 (en) 2018-07-16 2021-02-04 Baxalta GmbH Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
JP2022537200A (ja) 2019-06-19 2022-08-24 バイオベラティブ セラピューティクス インコーポレイテッド 血友病および低骨ミネラル密度を処置するための方法および組成物
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
US20230023826A1 (en) 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2021262963A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
CN117098996A (zh) * 2021-03-31 2023-11-21 美国血液技术公司 止血测量装置质量控制制剂
JP2024527252A (ja) 2021-06-14 2024-07-24 武田薬品工業株式会社 発現の増加した組み換えｆｖｉｉｉバリアントをコードするウイルスベクターを用いた、血友病ａの遺伝子療法
KR20240049332A (ko) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. 최적화된 인자 viii 유전자
EP4408874A1 (en) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
JPH0788399B2 (ja) * 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
EP0502976B1 (en) * 1989-12-01 1996-07-03 Pharming B.V. Production of recombinant polypeptides by bovine species and transgenic methods
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
MXPA03002256A (es) * 2000-09-19 2003-09-10 Univ Emory Factor viii modificado.
MXPA04005079A (es) * 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
DE60133541D1 (de) 2008-05-21
HK1051004A1 (en) 2003-07-18
CZ20023346A3 (cs) 2003-01-15
US7012132B2 (en) 2006-03-14
CA2400295A1 (en) 2001-09-20
HU227804B1 (en) 2012-03-28
CA2400295C (en) 2012-01-10
PL359672A1 (en) 2004-09-06
DE60133541T2 (de) 2009-05-07
BR122013026957A2 (enExample) 2004-12-07
FR16C0016I2 (fr) 2018-11-02
LU93049I2 (fr) 2016-06-27
HUP0300586A2 (hu) 2003-06-28
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
KR20020081426A (ko) 2002-10-26
US20030068785A1 (en) 2003-04-10
CY2016011I1 (el) 2016-10-05
MXPA02008798A (es) 2003-04-25
ME00601B (me) 2011-12-20
AU2001238416B2 (en) 2004-09-02
PT1280540E (pt) 2008-06-09
KR100485525B1 (ko) 2005-04-28
UA75064C2 (en) 2006-03-15
ATE391512T1 (de) 2008-04-15
EP1280540B1 (en) 2008-04-09
FR16C0016I1 (enExample) 2016-04-29
US6458563B1 (en) 2002-10-01
RU2002124123A (ru) 2004-03-27
LTC1280540I2 (lt) 2020-05-25
US20050079584A1 (en) 2005-04-14
US7122634B2 (en) 2006-10-17
BRPI0109131B1 (pt) 2020-08-25
NO2016007I2 (no) 2016-05-10
BE2016C024I2 (enExample) 2020-01-30
CY2016011I2 (el) 2016-10-05
NZ520799A (en) 2004-06-25
JP2003526358A (ja) 2003-09-09
CN1191360C (zh) 2005-03-02
BRPI0109131B8 (pt) 2021-07-06
NO331935B1 (no) 2012-05-07
NO20024296L (no) 2002-11-08
EE05075B1 (et) 2008-10-15
EP1280540A4 (en) 2004-11-03
EE200200510A (et) 2004-02-16
NL300808I2 (nl) 2020-12-21
ES2304379T3 (es) 2008-10-16
YU68002A (sh) 2005-11-28
CY1108179T1 (el) 2014-02-12
EP1280540A1 (en) 2003-02-05
NO2016007I1 (no) 2016-05-10
DK1280540T3 (da) 2008-07-14
IL151371A (en) 2010-12-30
HUS1600020I1 (hu) 2016-06-28
BR0109131A (pt) 2004-12-07
PL202936B1 (pl) 2009-08-31
SK286205B6 (sk) 2008-05-06
BR122013026957A8 (pt) 2017-02-21
SI1280540T1 (sl) 2008-08-31
JP4044337B2 (ja) 2008-02-06
HUP0300586A3 (en) 2006-11-28
CZ298250B6 (cs) 2007-08-01
ZA200206810B (en) 2003-11-26
IL151371A0 (en) 2003-04-10
CN1416348A (zh) 2003-05-07
SK14392002A3 (sk) 2003-06-03
WO2001068109A1 (en) 2001-09-20
RS50364B (sr) 2009-11-10
AU3841601A (en) 2001-09-24
MEP8209A (en) 2011-12-20

Similar Documents

Publication Publication Date Title
NL300808I1 (enExample)
PT1200105E (pt) Factor viii modificado
EP1194164B8 (en) Prion protein peptides and uses thereof
GB0225474D0 (en) Therapeutic agents
DK1200418T3 (da) Nematodicide trifluorbutener
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
GB0108592D0 (en) Therapeutic agents
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
DK1244435T5 (da) Polyhydroxylerede, aromatiske forbindelser til behandling af amyloidose og alpha-synuclein fibril sygdomme
ATE254461T1 (de) Behandlung von augenschmerzen
IL145068A0 (en) The use of glycine betaine to prepare a pharmaceutical composition
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
TR200200278T2 (tr) Kalsilitik bileşimler
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.